Scope and Limitations of Exploiting the Ability of the Chemosensitizer NV716 to Enhance the Activity of Tetracycline Derivatives against Pseudomonas aeruginosa

  • Molecules. 2023 May 23;28(11):4262. doi: 10.3390/molecules28114262.
Margot Draveny  1  2 Clémence Rose  3 Alexis Pinet  3 Laurent Ferrié  3 Bruno Figadère  3 Jean-Michel Brunel  1 Muriel Masi  1  2
Affiliations
  • 1. MCT, INSERM U1261, UMR_MD1, Aix-Marseille Univ. & IRBA SSA, 27 Boulevard Jean Moulin, 13005 Marseille, France.
  • 2. Synchrotron SOLEIL, L'Orme des Merisiers, Départementale 128, 91190 Saint-Aubin, France.
  • 3. BioCIS, Bâtiment H. Moissan, Université Paris-Saclay, CNRS, 91400 Orsay, France.
Abstract

The spread of Antibiotic resistance is an urgent threat to global health that requires new therapeutic approaches. Treatments for pathogenic Gram-negative bacteria are particularly challenging to identify due to the robust OM permeability barrier in these organisms. One strategy is to use Antibiotic adjuvants, a class of drugs that have no significant Antibacterial activity on their own but can act synergistically with certain Antibiotics. Previous studies described the discovery and development of polyaminoisoprenyl molecules as Antibiotic adjuvants with an OM effect. In particular, the compound NV716 has been shown to sensitize Pseudomonas aeruginosa to Tetracycline antibiotics such as doxycycline. Here, we sought to explore the disruption of OM to sensitize P. aeruginosa to otherwise inactive antimicrobials using a series of Tetracycline derivatives in the presence of NV716. We found that OM disruption expands the hydrophobicity threshold consistent with Antibacterial activity to include hydrophobic molecules, thereby altering permeation rules in Gram-negative bacteria.

Keywords
Gram-negative bacteria; NV716; antibiotic adjuvant; antibiotic resistance; outer membrane.
Products